ReviewPharmacoEconomics1992
Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
Review in PharmacoEconomics, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.Journal of epidemiology and community health · 1998Pooled it
- Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy.Clinical drug investigation · 2000Article
- Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.PharmacoEconomics · 1997Review
- Review
- Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.Drugs · 1996Review
- Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.Drugs · 1995Review
- Costs of illness in cost-effectiveness analysis. A review of the methodology.PharmacoEconomics · 1994Review
- Using cost-effectiveness analysis for formulary decision making: from theory into practice.PharmacoEconomics · 1994Article
- Economic evaluation of pharmaceuticals: a European perspective.PharmacoEconomics · 1993Review
- Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents.PharmacoEconomics · 1992Article
- Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.PharmacoEconomics · 1992Review
- Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.PharmacoEconomics · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological and intervention study results support reduction of coronary heart disease (CHD) risk, and hence direct and indirect costs, by lowering plasma lipids. Cost-effectiveness of a lipid-lowering strategy thus depends significantly on the extent of plasma lipid decrease achieved. The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin is a well tolerated and highly effective antihyperlipidaemic agent. Despite a current lack of direct evidence that simvastatin reduces CHD incidence, the cost-effectiveness of the drug {in terms of years of life saved (YOLS)} has been studied, based on findings of epidemiological trials. Simvastatin 20 mg/day is more cost-effective than cholestyramine 4g 3 times daily, particularly in men and in those with a higher pretreatment cholesterol level ( greater than 8 mmol/L) and other risk factors. Cost-effectiveness is also enhanced if treatment is started at a younger age (35 to 45 years) and maintained for a defined period rather than lifelong. Thus, while additional direct comparative studies are needed to confirm this finding, present evidence suggests simvastatin is a cost-effective intervention in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.